Stimulant drug effects on attention deficit/hyperactivity disorder: A review of the effects of age and sex of patients

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2424-2433

  Cornforth, Christine ^a   Sonuga Barke, Edmund ^a,b   Coghill, David ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adhd; Age; Amfetamine; Attention deficit hyperactivity disorder; Gender; Medication; Methylphenidate; Moderation; Prediction; Psychopathology; Psychostimulants; Sex; Treatment response

Indexed keywords

PSYCHOSTIMULANT AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ATTENTION DEFICIT DISORDER; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 77955606610     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959827     Document Type: Review

References (145)

1. Taylor E, Sonuga-Barke E. Disorders of attention and activity. Rutter's Child Adolesc Psychiatry. In: Rutter M, Bishop D, Pine D, et al. Eds. Oxford: Blackwell-Wiley 2008.
2. Satterfield J, Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 1997; 36(12): 1726-35.
3. Swanson J, Swartz M, Estroff S, et al. Psychiatric impairment, social contact, and violent behavior: evidence from a study of outpatient-committed persons with severe mental disorder. Social Psychiatry Psychiatr Epidemiol 1998; 33 (Suppl 1): S86-94.
4. Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatrics 1998; 133(4): 544-51.
5. Schubiner H, Tzelepis SV, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61(4): 244-51.
6. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15(8): 476-95.
7. NICE. Attention deficit hyperactivity disorder: diagnosis and management of adhd in children, young people and adults. London: National Institute for Health and Clin Excellence 2008.
8. Barkley R. Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract 2004; 10(1): 39-56.
9. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409-32.
10. Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100(6): E6.
11. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004; 6(5): 416-20.
12. Mitler MM, Erman M, Hajdukovic R. Amphetamines and narcolepsy. The treatment of excessive somnolence with stimulant drugs. Sleep 1993; 16(3): 203-6.
13. Swanson J, Volkow N. Pharmacokinetic and pharmacodynamic properties of methylphenidate in humans, in stimulant drugs and ADHD: Basic and clinical neuroscience. Solanto MV, Arnsten AF, Castellanos FX, Eds. New York: Oxford University Press 2001; pp. 259-82.
14. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinetics 1999; 37(6): 457-70.
15. Anderson VR, Scott LJ. Methylphenidate transdermal system - In attention-deficit hyperactivity disorder in children. Drugs 2006; 66(8): 1117-26.
16. Sonuga-Barke EJS, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004; 4: 28.
17. Swanson J, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004; 113: 206-16.
18. Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effect of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57(11): 1410-5.
19. Grace AA. Psychostimulant actions on dopamine and limbic system function: Relevance to the pathophysiology and treatment of ADHD, in Stimulant drugs and ADHD: Basic and Clin neuroscience, Solanto MV, Arnsten AF, Castellanos FX, Eds. New York: Oxford University Press 2001; pp. 134-57.
20. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21(2): RC121.
21. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biolog Psychiatry 2005; 57(11): 1377-84.
22. Kuczenski R, Segal D. Effects of methylphenidate on extracellular dopamine, serotonin, norepinephrine: comparison with amphetamine. J Neurochem 1997; 68(5): 2032-7.
23. Solanto MV, Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94(1): 127-52.
24. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54(12): 1073-80.
25. Serra-Pinheiro MA, Mattos P, Souza I, et al. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Arquivos De Neuro-Psiquiatria 2004; 62(2B): 399-402.
26. Mehta MA, Owen AM, Sahakian BJ, et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20(6).
27. Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 62(9): 954-62.
28. Shiels K, Hawk LW, Jr, Reynolds B, et al. Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2009; 17(5): 291-301.
29. Kosten T, Kosten A, McDougle C, et al. Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry 1996; 39(2): 147-8.
30. Dreher JC, Schmidt PJ, Kohn P, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Nat Acad Sci 2007; 104(7): 2465-70.
31. Bitsakou P, Psychogiou L, Thompson M, et al. Delay aversion in attention deficit/hyperactivity disorder: an empirical investigation of the broader phenotype. Neuropsychologia 2009; 47(2): 446-56.
32. Kuntsi J, Stevenson J, Psychological mechanisms in hyperactivity: II. The role of genetic factors. J Child Psychol Psychiatr Allied Disciplines 2001; 42(2): 211-9.
33. Sonuga-Barke EJS. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 2003; 27(7): 593-604.
34. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49(2): 81-96.
35. Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. J Am Acad Child Adolesc Psychiatry 2006; 45(2): 142-8.
36. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45(11): 1284-93.
37. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. J Child Neurol 2008; 23(9): 981-90.
38. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attentiondeficit/hyperactivity disorder in children and adults. Clin Therap 2009; 31(1): 142-76.
39. Blockmans D, Persoons P, Van Houdenhove B, et al. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 2006; 119(2): 167.e23-30.
40. Huang CC, Shiah IS, Chen HK, et al. Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression. In: Asia Pacific Regional Meeting 3rd Collegium International Neuro-Psychopharmacologium. Bangkok: Lippincott Williams & Wilkins 2007; pp. 245-7.
41. Sonuga-Barke EJ, Coghill D, Wigal T, De Backer M, Swanson J. Adverse reactions to methylphenidate treatment for ADHD: Structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009; 19(6): 683-90.
42. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD, in 23rd International conference on pharmacoepidemiology and therapeutic risk management, am academy pediatrics. Quebec City: American Academy Pediatrics 2007; pp. E75-80.
43. Graham J, Coghill D, Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22(3): 213-37.
44. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology 2007; 194(2): 197-209.
45. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Therapeut 2006; 28(11): 1892-908.
46. dosReis S, Butz A, Lipkin PH, et al. Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African Am families in an inner city community. J Behav Health Serv Res 2006; 33(4): 423-30.
47. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009; 194(3): 273-7.
48. Buitelaar JK, Vandergaag RJ, Swaabbarneveld H, et al. Prediction of clinical response to methylphenidate in children with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34(8): 1025-32.
49. Gomez R, Harvey J, Quick C, et al. DSM-IV AD/HD: Confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatr Allied Disciplines 1999; 40(2): 265-74.
50. Mukhopadhyay M, Misra S, Mitra T, et al. Attention deficit hyperactivity disorder. Ind J Pediatrics 2003; 70(10): 789-92.
51. St Sauver JL, Barbaresi WJ, Katusic SK, et al. Early life risk factors for attention-deficit/hyperactivity disorder: a population-based cohort study. Mayo Clin Proc 2004; 79(9): 1124-31.
52. NHS Quality Improvement Scotland. ADHD Service Over Scotland. Edinburgh: NHS 2008.
53. Berkson J, Limitations of the application of the fourfold table analysis to hospital data. Biometrics 1946; 2: 47-53.
54. Gaub M, Carlson CL, Gender differences in ADHD: a metaanalysis and critical review. J Am Acad Child Adolesc Psychiatry 1997; 36(8): 1036-45.
55. Novik TS, Hervas A, Ralston SJ, et al. Influence of gender on attention-deficit/hyperactivity disorder in Europe - ADORE. Eur Child Adolesc Psychiatry 2006; 15(1): I/15-I/24.
56. Andersen SL, Teicher MH. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000; 24(1): 137-41.
57. Rucklidge JJ, Tannock R. Neuropsychological profiles of adolescents with ADHD: effects of reading difficulties and gender. J Child Psychol Psychiatr Allied Disciplines 2002; 43(8): 988-1003.
58. Craft R, Sex differences in drug- and non-drug-induced analgesia. Life Sci 2003; 72(24): 2675-88.
59. Kosten T, Gawin F, Kosten T, et al. Gender differences in cocaine use and treatment response. J Subst Abuse Treat 1993; 10(1): 63-6.
60. Booze RM, Wood ML, Welch MA, et al. Estrous cyclicity and behavioral sensitization in female rats following repeated intravenous cocaine administration. Pharmacol Biochem Behav 1999; 64(3): 605-10.
61. Gorski JC, Vannaprasaht S, Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Therap 2003; 74(3): 275-87.
62. Sowinski KM, Abel SR, Clark WR, et al. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 1999; 19(4 I): 442-6.
63. US General Accounting Office. Adverse Drug Events. Washington DC: US General Accounting Office 2000.
64. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. New Eng J Med 2002; 347(18): 1403-11.
65. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinetics 1997; 33(5): 328-43.
66. Hu M, Crombag HS, Robinson TE, et al. Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 2004; 29(1): 81-5.
67. Roth ME, Carroll ME. Sex differences in the escalation of intravenous cocaine intake following long- or short-access to cocaine selfadministration. Pharmacol Biochem Behav 2004; 78(2): 199-207.
68. Mozley LH, Gur RC, Mozley PD, et al. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001; 158(9): 1492-9.
69. Rivest R, Falardeau P, Dipaolo T. Brain dopamine transporter - gender differences and effect of chronic haloperidol. Brain Res 1995; 692(1-2): 269-72.
70. Bhatt SD, Dluzen DE, Bhatt SD, et al. Dopamine transporter function differences between male and female CD-1 mice. Brain Res 2005; 1035(2): 188-95.
71. Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [I-123]FP-CIT SPET in healthy volunteers. Eur J Nuclear Med 2000; 27(7): 867-9.
72. Andersen SL, Dumont NL, Teicher MH, et al. Differences in behavior and monoamine laterality following neonatal clomipramine treatment. Develop Psychobiol 2002; 41(1): 50-7.
73. Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Therap 2007; 81(3): 346-53.
74. Markowitz JS, Straughn AB, Patrick KS, et al. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23(10): 1281-99.
75. Quinn PO. Treating adolescent girls and women with ADHD: gender-specific issues. J Clin Psychol 2005; 61(5): 579-87.
76. Justice AJH, de Wit H, Acute effects of estradiol pretreatment on the response to d-amphetamine in women. Neuroendocrinology 2000; 71(1): 51-9.
77. Dluzen DE, Liu B, Dluzen DE, et al. Gender differences in methamphetamine use and responses: a review. Gender Med 2008; 5(1): 24-35.
78. White TL, Justice AJ, de Wit H, Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 2002; 73(4): 729-41.
79. Spencer T, Biederman J, Mick E, Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. J Pediat Psychol 2007; 32(6): 631-42.
80. Biederman J, Faraone S, Taylor A, et al. Diagnostic continuity between child and adolescent ADHD: Findings from a longitudinal clinical sample. J Am Acad Child Adolesc Psychiatry 1998; 37(3): 305-13.
81. Mannuzza S, Klein R, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155(4): 493-8.
82. Wilens T, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Ann Rev Med 2002; 53: 113-31.
83. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for psychopharmacology. J Psychopharmacol 2007; 21(1): 10-41.
84. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48(5): 484-500.
85. Canese R, Adriani W, Marco EM, et al. Peculiar response to methylphenidate in adolescent compared to adult rats: A phMRI study. Psychopharmacology 2009; 203(1): 143-53.
86. Mathews IZ, Waters P, McCormick CM. Changes in hyporesponsiveness to acute amphetamine and age differences in tyrosine hydroxylase immunoreactivity in the brain over adolescence in male and female rats. Develop Psychobiol 2009; 51(5): 417-28.
87. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine- 123-beta-CIT SPECT. J Nucl Med 1995; 36(7): 1175-81.
88. Volz TJ, Farnsworth SJ, Rowley SD, et al. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse 2009; 63(2): 147-51.
89. Mikami AY, Cox DJ, Davis MT, et al. Sex Differences in Effectiveness of Extended-Release Stimulant Medication among Adolescents with Attention-Deficit/Hyperactivity Disorder. J Clin Psychol Med Settings 2009; 16(3): 233-42.
90. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity - are there true nonresponders? Psychiatr Res 1991; 36(2): 141-55.
91. Elia J, Welsh PA, Guliotta CS, et al. Classroom academic performance: Improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatr Allied Disciplines 1993; 34(5): 785-804.
92. MTA. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatr 1999; 56(12): 1088-96.
93. Sharp WS, Walter JM, Marsh WL, et al. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999; 38(1): 40-7.
94. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Nat Med Assoc 2005; 97(10 Suppl): 11S-6.
95. Amery B, Minichiello MD, Brown GL. Aggression in hyperactive boys: response to d-amphetamine. J Am Acad Child Psychiatr 1984; 23(3): 291-4.
96. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Develop Behav Pediatrics 2006; 27(1): 1-10.
97. Biederman J, Wigal SB, Spencer TJ, et al. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attentiondeficit/ hyperactivity disorder. Clin Therap 2006; 28(2): 280-93.
98. Wigal T, Kollins S, Squires L, et al. The effect of gender on treatment outcomes over 13 hours in an analog classroom study of children with attention deficit hyperactivity disorder treated with lisdexamfetamine dimesylate. US Psychiatric and Mental Health Congress Conference. 2009.
99. Zito JM, Safer DJ, dos Reis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283(8): 1025-30.
100. Kollins S, Greenhill L, Swanson J, et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry 2006; 45(11): 1275-83.
101. Firestone P, Musten LM, Pisterman S, et al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: A double- blind placebocontrolled study. J Child Adolesc Psychopharmacol 1998; 8(1): 13-25.
102. Handen BL, Feldman HM, Lurier A, et al. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999; 38(7): 805-12.
103. Musten LM, Firestone P, Pisterman S, et al. Effects of methylphenidate on preschool children with ADHD: Cognitive and behavioral functions. J Am Acad Child Adolesc Psychiatry 1997; 36(10): 1407-15.
104. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006; 45(11): 1304-13.
105. Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatr 2006; 45(11): 1294-302.
106. Biederman J, Faraone S, Mick E, et al. Psychiatric comorbidity among referred juveniles with major depression - fact or artifact. J Am Acad Child Adolesc Psychiatry 1995; 34(5): 579-90.
107. Wong I, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) - a pharmacoepidemiological and qualitative study. Health Technol Assess 2009; 13(50): 1-144.
108. Biederman J, Wilens T, Mick E, et al. Psychoactive Substance Use Disorders in Adults with Attention-Deficit Hyperactivity Disorder (Adhd) - Effects of Adhd and Psychiatric Comorbidity. Am J Psychiatry 1995; 152(11): 1652-8.
109. Stein MA, Seymour KE, Black DO, et al. Effects and side effects of Concerta methylphenidate (MPH) in children with ADHD and comorbid internalizing symptoms. Pediatric Res 2003; 53(4): 555a.
110. Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45(4): 408-14.
111. Smith BH, Waschbusch DA, Willoughby MT, et al. The efficacy, safety, and practicality of treatments for adolescents with attentiondeficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 2000; 3(4): 243-67.
112. Spencer T, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, doubleblind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Therap 2006; 28(3): 402-18.
113. Findling RL, Short EJ, Manos MJ. Developmental aspects of psychostimulant treatment in children and adolescents with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001; 40(12): 1441-7.
114. Jadad AR, Booker L, Gauld M, et al. The treatment of attentiondeficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and metaanalyses. Canadian J Psychiatr-Rev Canadienne De Psychiatrie 1999; 44(10): 1025-35.
115. Chen CY, Gerhard T, Winterstein AG. Determinants of Initial Pharmacological Treatment for Youths with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2009; 19(2): 187-95.
116. Coghill D. Understudied and underrecognised. Adv Psychiatr Treat 2004; 10(5): 338-40.
117. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288(14): 1740-8.
118. Kooij JJS, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004; 34(6): 973-82.
119. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63(10): 981-9.
120. Rosler M, Fischer R, Ammer R, et al. A randomised, placebocontrolled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatr Clin Neurosci 2009; 259(6): 120-9.
121. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41(11): 1059-63.
122. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57(5): 456-63.
123. Spencer T, Wilens T, Biederman J, et al. A double blind crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52(6): 434-43.
124. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23(7): 733-44.
125. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24(1): 24-9.
126. Buitelaar JK, Ramos-Quiroga JA, Casas M, et al. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2009; 5: 457-66.
127. Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2000; 61(6): 414-7.
128. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2001; 58(8): 775-82.
129. Weber J, Siddiqui MAA. Lisdexamfetamine dimesylate in attention-deficit hyperactivity disorder in adults. CNS Drugs 2009; 23(5): 419-25.
130. Ramos-Quiroga A, Kooij S, Trott GE, et al. Factors predicting treatment outcome with long-acting methylphenidate in adults with attention deficit hyperactivity disorder (ADHD). ECNP Congress. 2009.
131. Pelham WE, Walker JL, Sturges J, et al. Comparative effects of methylphenidate on ADD girls and ADD boys. J Am Acad Child Adolesc Psychiatry 1989; 28(5): 773-6.
132. Barkley R. Hyperactive girls and boys: Stimulant drug effects on mother-child interactions. J Child Psychol Psychiatr Allied Disciplines 1989; 30(3): 379-90.
133. Sonuga-Barke EJS, Coghill D, Markowitz JS, et al. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 2007; 46(6): 701-10.
134. Owens E, Hinshaw S, Kraemer H, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003; 74(3): 540-52.
135. Swanson J, Nolan W, Pelham W. SNAP rating scale. Educ Resources Educ 1982.
136. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006; 18(2): 107-13.
137. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication - a controlled trial of methylphenidate in boys with disruptive behavior. Psychol Med 1987; 17(1): 121-43.
138. Pelham WE, Voddehamilton M, Murphy DA, et al. The effects of methylphenidate on ADHD adolescents in recreational, peer group and classroom settings. J Clin Child Psychol 1991; 20(3): 293-300.
139. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 2006; 59(10): 966-74.
140. Thompson MJJ, Laver-Bradbury C, Ayres M, et al. A small-scale randomized controlled trial of the revised new forest parenting programme for preschoolers with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry 2009; 18(10): 605-16.
141. Sonuga-Barke EJS, Daley D, Thompson M, et al. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: A randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry 2001; 40(4): 402-8.
142. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disor-der: a systematic review. Eur Child Adolesc Psychiatry 2010; 19(2): 83-105.
143. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008; 14(15): 1512-1524.
144. Ding YS, Lin KS, Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des 2006; 12(30): 3831-3845.
145. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 2005; 11(25): 3237-3245.